Across TCGA pan-cancer cohorts, MORC1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MORC1 data layer compared with 23 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MORC1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MORC1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
LUAD, HNSC, and PDAC are the cancer types where MORC1 mass-spec protein most reproducibly stratifies survival.